Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(3.49)
# 908
Out of 5,053 analysts
53
Total ratings
32.5%
Success rate
12.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VSTM Verastem | Assumes: Overweight | n/a | $8.25 | - | 1 | Oct 16, 2025 | |
| ACLX Arcellx | Assumes: Neutral | $88 | $85.74 | +2.64% | 1 | Oct 9, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Overweight | n/a | $18.30 | - | 3 | Sep 8, 2025 | |
| LEGN Legend Biotech | Assumes: Overweight | $55 → $66 | $31.59 | +108.93% | 1 | Aug 27, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Overweight | n/a | $29.37 | - | 1 | Jul 17, 2025 | |
| RNA Avidity Biosciences | Reiterates: Overweight | $96 | $69.84 | +37.46% | 5 | Jun 27, 2025 | |
| PRTA Prothena Corporation | Reiterates: Neutral | n/a | $10.53 | - | 2 | Jun 20, 2025 | |
| CDTX Cidara Therapeutics | Reiterates: Overweight | n/a | $103.79 | - | 2 | Jun 10, 2025 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $9.02 | - | 4 | Apr 1, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $5.05 | - | 4 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $13.91 | -6.47% | 2 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.23 | - | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $54.58 | - | 4 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $105.98 | - | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $41.26 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.95 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $35.00 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $156.26 | +86.87% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $421.20 | -12.16% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.52 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.36 | - | 1 | May 30, 2017 |
Verastem
Oct 16, 2025
Assumes: Overweight
Price Target: n/a
Current: $8.25
Upside: -
Arcellx
Oct 9, 2025
Assumes: Neutral
Price Target: $88
Current: $85.74
Upside: +2.64%
Summit Therapeutics
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $18.30
Upside: -
Legend Biotech
Aug 27, 2025
Assumes: Overweight
Price Target: $55 → $66
Current: $31.59
Upside: +108.93%
Scholar Rock Holding
Jul 17, 2025
Initiates: Overweight
Price Target: n/a
Current: $29.37
Upside: -
Avidity Biosciences
Jun 27, 2025
Reiterates: Overweight
Price Target: $96
Current: $69.84
Upside: +37.46%
Prothena Corporation
Jun 20, 2025
Reiterates: Neutral
Price Target: n/a
Current: $10.53
Upside: -
Cidara Therapeutics
Jun 10, 2025
Reiterates: Overweight
Price Target: n/a
Current: $103.79
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $9.02
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $5.05
Upside: -
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $13.91
Upside: -6.47%
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.23
Upside: -
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $54.58
Upside: -
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $105.98
Upside: -
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $41.26
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.95
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $35.00
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $156.26
Upside: +86.87%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $421.20
Upside: -12.16%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.52
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.36
Upside: -